Developer docs
API playgroundTry for free, no card

Search company profiles

FEMSelect

Full company profile

uuid0000iyb

Namestring
FEMSelect
Legal namestring
FEMSelect Ltd.
Websiteurl
femselect.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

FEMSelect is a women-led medical technology company developing minimally invasive solutions for pelvic floor disorders. Originally founded in Israel in 2012 as POP Medical Solutions and renamed FEMSelect in 2019, the company relocated its headquarters to Newark, Delaware in 2025 to align with its largest commercial market. FEMSelect serves urogynecologists, pelvic floor reconstructive surgeons, and women suffering from pelvic organ prolapse (POP) and urinary incontinence, conditions affecting more than half of women over 50 and nearly one in three women, respectively.

The company's core technology is EnPlace, an FDA-cleared (510(k), 2016) and CE-marked (2018) mesh-free, minimally invasive pelvic floor ligament fixation system. EnPlace uses a patented Finger Guide Delivery System and Anchor Inserter to enable precise anchor placement to the sacrospinous ligaments through a small vaginal incision, without deep dissection or mesh implants. The procedure is performed in approximately 30 minutes (vs. 75-120 minutes for traditional surgical approaches) as a same-day outpatient intervention, with clinical data demonstrating a 92% surgical success rate over four years and 6,000+ procedures performed globally as of February 2026. The portfolio has expanded through distribution partnerships to include Elitone and Elitone URGE (FDA-cleared at-home neuromuscular stimulation devices for stress and urge incontinence, serving 30,000 women cumulatively) and biologic implants (VNEW, DermaPure) distributed through ARMS Medical.

FEMSelect monetizes through three revenue streams: (1) direct sales of EnPlace kits to hospitals, ambulatory surgery centers, and physicians, supported by a 3-step physician certification process (online modules, wet lab, case proctoring) and a national Premier, Inc. GPO agreement covering approximately two-thirds of US healthcare providers; (2) direct-to-consumer e-commerce sales of Elitone devices at $36/month subscription or $429 one-time purchase, with Medicare Part B and HSA/FSA eligibility; and (3) distribution of biologic implants via ARMS Medical's network of 200+ surgeons. International expansion is enabled by exclusive distribution partners in Mexico, Chile, Costa Rica, Panama, and Cyprus. The company is backed by New Age Ventures, Triventures, Robin Hood Ventures, RAD BioMed, Nordwand Capital, Avea Ventures, and Terra Verde Comp, having raised over $12.5M in disclosed funding across Series A, Series B, and follow-on rounds.

Short descriptiontext

FEMSelect is a women's health medical technology company that commercializes EnPlace, an FDA-cleared mesh-free minimally invasive system for pelvic organ prolapse repair, and distributes Elitone at-home neuromuscular stimulation devices for urinary incontinence. The company serves urogynecologists, pelvic floor surgeons, and women with pelvic floor disorders across the US and international markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pelvic floor repair, minimally invasive surgery, women's health devices, urinary incontinence treatment, pelvic organ prolapse
Industry3 codes
PRIMARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAJAE
Urogynecology & Pelvic Reconstructive Surgery (Female Pelvic Medicine)
SECONDARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Women's Pelvic Health Medical Devices
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1EnPlace Medical Device Sales
TypeHardware Sales
Description

FEMSelect generates revenue through the sale of its EnPlace surgical system to hospitals, ambulatory surgery centers, and physicians. The procedure takes approximately 30 minutes vs. 75-120 minutes for traditional approaches, making it economically attractive for healthcare providers.

femselect.com
2Elitone Consumer Device Sales
TypeSubscription Recurring
Description

Elitone and Elitone URGE are sold directly to consumers at $36/month (subscription) or $429 one-time purchase. Products are HSA/FSA eligible with Medicare coverage available through Original Medicare Part B.

femselect.com
3Biologic Implant Distribution
TypeHardware Sales
Description

Through the ARMS Medical distribution agreement, FEMSelect distributes biologic implant portfolio including VNEW precut decellularized dermal allografts and DermaPure products for pelvic reconstruction, complementing the EnPlace system.

prnewswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain
Pricing details2 tiers
1Elitone for stress urinary incontinence
ModelSubscriptionBilling cadenceMonthly
Notes

As low as $36/month or $429 one-time purchase. HSA/FSA eligible. Original Medicare Part B eligible (billed as 13-month rental, after which patient owns the device).

femselect.com
2Elitone URGE for urge incontinence/overactive bladder
ModelSubscriptionBilling cadenceMonthly
Notes

Same pricing structure as Elitone - $36/month or $429 one-time. FDA-cleared for over-the-counter use without prescription.

femselect.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1EnPlace
Description

FDA-cleared minimally invasive mesh-free system for pelvic organ prolapse repair

femselect.com
+2 more records
Core offering1 text field

FEMSelect develops, manufactures, and distributes medical devices for women's pelvic health. Its core product is the EnPlace system, an FDA-cleared, minimally invasive, mesh-free device for pelvic organ prolapse repair that uses a patented Finger Guide delivery system to anchor sutures to the sacrospinous ligament without deep dissection. The company also distributes Elitone and Elitone URGE, FDA-cleared at-home neuromuscular stimulation devices for stress and urge urinary incontinence, and biologic implants (VNEW, DermaPure) through a partnership with ARMS Medical.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 6,000+ procedures performed globally
+6 more records
Product overview1 text field

FEMSelect is a women-led medical technology company offering a platform of pelvic health solutions. The core product is EnPlace®, an FDA-cleared minimally invasive mesh-free system for pelvic organ prolapse repair, complemented by distributed consumer medical devices (Elitone® and Elitone URGE) for urinary incontinence treatment. Through partnerships with ARMS Medical, the portfolio also includes biologic implants (VNEW® and DermaPure®) for pelvic reconstruction. The EnPlace system consists of an Anchor Inserter and patented Finger Guide delivery system, while Elitone products are external neuromuscular stimulation devices used at home. This diversified platform addresses pelvic organ prolapse, stress urinary incontinence, urge incontinence, and pelvic reconstruction needs.

Product and service5 records
1EnPlace
CategorySurgical Medical Device (Pelvic Organ Prolapse Repair)
Description

FDA-cleared, minimally invasive, mesh-free system for pelvic organ prolapse repair. Uses the patented Finger Guide Delivery System to enable anchor placement through the vaginal wall and secure sutures to the sacrospinous ligament without deep dissection or mesh implants. Designed for same-day outpatient procedures for urogynecologists and pelvic floor reconstructive surgeons.

2Elitone
CategoryConsumer Medical Device (Urinary Incontinence Treatment)
Description

FDA-cleared external medical device for at-home treatment of stress urinary incontinence. Uses neuromuscular electrical stimulation through gel pads applied to the perineal area to tone pelvic floor muscles, worn 20 minutes daily for 6 weeks. Sold directly to consumers via femselect.com for $36/month subscription or $429 one-time purchase, with HSA/FSA eligibility and Original Medicare Part B coverage.

3Elitone URGE
CategoryConsumer Medical Device (Urinary Incontinence Treatment)
Description

FDA-cleared external medical device for at-home treatment of urge urinary incontinence and overactive bladder. Uses calming neuromuscular electrical stimulation to reduce sudden urges to urinate, applied 20 minutes daily for 6 weeks. FDA-cleared for over-the-counter use without prescription, sold direct-to-consumer at the same pricing as Elitone.

4VNEW
CategoryBiologic Implant (Pelvic Reconstruction)
Description

Precut decellularized dermal allograft for pelvic reconstruction procedures. Distributed by FEMSelect through the ARMS Medical partnership to complement the EnPlace surgical system.

5DermaPure
CategoryBiologic Implant (Pelvic Reconstruction)
Description

Dermal allograft product for pelvic reconstruction procedures. Distributed by FEMSelect through the ARMS Medical partnership to complement the EnPlace surgical system.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Market research and distributor identification partner supporting FEMSelect's Latin America expansion. medikana helped identify exclusive distribution partners in key markets including Mexico, Chile, Costa Rica, and Panama.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-16
Description

Strategic distribution agreement for biologic implant portfolio including VNEW precut decellularized dermal allografts and DermaPure products for pelvic reconstruction. ARMS Medical brings experience treating over 10,000 patients and engaging 200 surgeons nationwide. The partnership complements EnPlace and represents FEMSelect's capital-efficient strategy to build a diversified platform.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-22
Description

Strategic partnership to distribute Elitone and Elitone URGE, FDA-cleared at-home devices for urinary incontinence treatment. This partnership expands FEMSelect's portfolio from EnPlace (surgical prolapse repair) into the incontinence market, addressing a condition affecting nearly one in three women. The agreement supports FEMSelect's growth strategy to build a comprehensive platform of women's health solutions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-01
Description

National group purchasing agreement providing FEMSelect access to Premier's network of healthcare providers. Premier serves approximately two-thirds of all healthcare providers in the United States, enabling broader adoption of EnPlace as a minimally invasive treatment option.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Axonics acquired Bulkamid (hydrogel urethral bulking for SUI) from Contura in 2021 for $200M. Directly comparable: Bulkamid and EnPlace both target the same urogynecology/female pelvic medicine surgeon base for stress urinary incontinence and apical prolapse, with the same physician training and GPO distribution model. FEMSelect board member Rakesh Tailor led the Bulkamid-to-Axonics exit, making this the closest comparable.

TypeBroad incumbent
Description

Global medtech incumbent with a dedicated Pelvic Floor Health franchise offering Restorelle mesh, Altis single-incision sling, and surgical continence products. FEMSelect's CCO Joel Chechik previously led sales at Coloplast, and the companies target the same FPMRS surgeon base with overlapping pelvic floor fixation and incontinence offerings, though Coloplast operates at vastly greater scale across multiple product lines.

TypeBroad incumbent
Description

Major medtech incumbent with a Pelvic Health segment offering mid-urethral slings, mesh products, and the Xenform biologic matrix for pelvic reconstruction. Comparable because it competes with both EnPlace (surgical POP repair) and FEMSelect's ARMS Medical biologic implants (VNEW/DermaPure) for hospital budget and physician mindshare.

TypeBroad incumbent
Description

J&J's surgical device arm and the historical leader in women's pelvic floor surgery, with the Gynecare TVT sling and Prolift mesh product families. Renee Selman (FEMSelect's Executive Chairwoman) was former Worldwide President of Ethicon Women's Health and Urology. Comparable as the dominant incumbent that EnPlace is positioned to displace for mesh-averse surgeons.

TypeDirect peer
Description

Private women's health medtech company focused exclusively on pelvic floor disorders, offering Desara and Vertessa sling systems for stress urinary incontinence and Desara Pro for pelvic organ prolapse. Highly comparable as a similarly-sized specialty player competing in the same FPMRS surgeon channel with single-incision pelvic floor fixation devices.

TypeBroad incumbent
Description

Women's health-focused subsidiary of CooperCompanies providing a broad portfolio including the Frigg, Restora, and Sundance sling systems for pelvic floor disorders. Comparable as a diversified women's health platform serving the same urogynecology specialist base, though CooperSurgical spans fertility, obstetrics, and surgical solutions beyond pelvic floor.

7InControl Medical
TypeDirect peer
Description

Maker of Apex and Attain at-home neuromuscular stimulation devices for stress and urge incontinence, FDA-cleared for OTC use. Directly competes with FEMSelect's distributed Elitone and Elitone URGE products in the same direct-to-consumer channel at comparable price points, addressing the same female urinary incontinence patient population.

TypeEmerging player
Description

Developer of the INNOVO non-invasive pelvic floor stimulation device for stress urinary incontinence, sold primarily via direct-to-consumer channels in Europe and the US. Comparable as a non-surgical, at-home electrical stimulation alternative competing with Elitone for the same conservative-treatment patient segment.

TypeEmerging player
Description

Boston-based women's health startup developing the leva Pelvic Health System, an FDA-cleared digital pelvic floor training device for stress urinary incontinence. Comparable as a venture-backed, single-focus women's pelvic health company with both a connected device offering and physician-channel distribution competing for similar patient and provider mindshare.

TypeRegional player
Description

Spain-based medical device company specializing in pelvic floor reconstruction products including the Contasure and Needleless single-incision sling systems. Comparable as a specialty competitor offering minimally invasive mesh and sling alternatives for POP and SUI, primarily serving European and Latin American markets where FEMSelect is now expanding via distribution partners.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FEMSelect

Women's Pelvic Health Medical Devicesfemselect.com

FEMSelect is a women's health medical technology company that commercializes EnPlace, an FDA-cleared mesh-free minimally invasive system for pelvic organ prolapse repair, and distributes Elitone at-home neuromuscular stimulation devices for urinary incontinence. The company serves urogynecologists, pelvic floor surgeons, and women with pelvic floor disorders across the US and international markets.

What FEMSelect does

FEMSelect is a women-led medical technology company developing minimally invasive solutions for pelvic floor disorders. Originally founded in Israel in 2012 as POP Medical Solutions and renamed FEMSelect in 2019, the company relocated its headquarters to Newark, Delaware in 2025 to align with its largest commercial market. FEMSelect serves urogynecologists, pelvic floor reconstructive surgeons, and women suffering from pelvic organ prolapse (POP) and urinary incontinence, conditions affecting more than half of women over 50 and nearly one in three women, respectively.

The company's core technology is EnPlace, an FDA-cleared (510(k), 2016) and CE-marked (2018) mesh-free, minimally invasive pelvic floor ligament fixation system. EnPlace uses a patented Finger Guide Delivery System and Anchor Inserter to enable precise anchor placement to the sacrospinous ligaments through a small vaginal incision, without deep dissection or mesh implants. The procedure is performed in approximately 30 minutes (vs. 75-120 minutes for traditional surgical approaches) as a same-day outpatient intervention, with clinical data demonstrating a 92% surgical success rate over four years and 6,000+ procedures performed globally as of February 2026. The portfolio has expanded through distribution partnerships to include Elitone and Elitone URGE (FDA-cleared at-home neuromuscular stimulation devices for stress and urge incontinence, serving 30,000 women cumulatively) and biologic implants (VNEW, DermaPure) distributed through ARMS Medical.

FEMSelect monetizes through three revenue streams: (1) direct sales of EnPlace kits to hospitals, ambulatory surgery centers, and physicians, supported by a 3-step physician certification process (online modules, wet lab, case proctoring) and a national Premier, Inc. GPO agreement covering approximately two-thirds of US healthcare providers; (2) direct-to-consumer e-commerce sales of Elitone devices at $36/month subscription or $429 one-time purchase, with Medicare Part B and HSA/FSA eligibility; and (3) distribution of biologic implants via ARMS Medical's network of 200+ surgeons. International expansion is enabled by exclusive distribution partners in Mexico, Chile, Costa Rica, Panama, and Cyprus. The company is backed by New Age Ventures, Triventures, Robin Hood Ventures, RAD BioMed, Nordwand Capital, Avea Ventures, and Terra Verde Comp, having raised over $12.5M in disclosed funding across Series A, Series B, and follow-on rounds.

FEMSelect firmographics

Firmographics
Name
FEMSelect
Legal name
FEMSelect Ltd.
Website
https://femselect.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
FEMSelect is a women's health medical technology company that commercializes EnPlace, an FDA-cleared mesh-free minimally invasive system for pelvic organ prolapse repair, and distributes Elitone at-home neuromuscular stimulation devices for urinary incontinence. The company serves urogynecologists, pelvic floor surgeons, and women with pelvic floor disorders across the US and international markets.
Ownership category
akta.pro rank

FEMSelect industry classification

Industry
Product category
Women's Pelvic Health Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAA
Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKAJAE
Urogynecology & Pelvic Reconstructive Surgery (Female Pelvic Medicine)
SECONDARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Pelvic floor repair
  • Minimally invasive surgery
  • Women's health devices
  • Urinary incontinence treatment
  • Pelvic organ prolapse

Where FEMSelect is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

FEMSelect business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain

Revenue model

  1. EnPlace Medical Device Sales: FEMSelect generates revenue through the sale of its EnPlace surgical system to hospitals, ambulatory surgery centers, and physicians. The procedure takes approximately 30 minutes vs. 75-120 minutes for traditional approaches, making it economically attractive for healthcare providers.
  2. Elitone Consumer Device Sales: Elitone and Elitone URGE are sold directly to consumers at $36/month (subscription) or $429 one-time purchase. Products are HSA/FSA eligible with Medicare coverage available through Original Medicare Part B.
  3. Biologic Implant Distribution: Through the ARMS Medical distribution agreement, FEMSelect distributes biologic implant portfolio including VNEW precut decellularized dermal allografts and DermaPure products for pelvic reconstruction, complementing the EnPlace system.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyElitone for stress urinary incontinence
SubscriptionMonthlyElitone URGE for urge incontinence/overactive bladder

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

FEMSelect product offering

Product offering

Core offering

FEMSelect develops, manufactures, and distributes medical devices for women's pelvic health. Its core product is the EnPlace system, an FDA-cleared, minimally invasive, mesh-free device for pelvic organ prolapse repair that uses a patented Finger Guide delivery system to anchor sutures to the sacrospinous ligament without deep dissection. The company also distributes Elitone and Elitone URGE, FDA-cleared at-home neuromuscular stimulation devices for stress and urge urinary incontinence, and biologic implants (VNEW, DermaPure) through a partnership with ARMS Medical.

Product overview

FEMSelect is a women-led medical technology company offering a platform of pelvic health solutions. The core product is EnPlace®, an FDA-cleared minimally invasive mesh-free system for pelvic organ prolapse repair, complemented by distributed consumer medical devices (Elitone® and Elitone URGE) for urinary incontinence treatment. Through partnerships with ARMS Medical, the portfolio also includes biologic implants (VNEW® and DermaPure®) for pelvic reconstruction. The EnPlace system consists of an Anchor Inserter and patented Finger Guide delivery system, while Elitone products are external neuromuscular stimulation devices used at home. This diversified platform addresses pelvic organ prolapse, stress urinary incontinence, urge incontinence, and pelvic reconstruction needs.

Differentiator

Problem solved

Functional benefit

Brands

  • EnPlace: FDA-cleared minimally invasive mesh-free system for pelvic organ prolapse repair
  • Elitone
  • Elitone URGE

Products and services

  • EnPlace FDA-cleared, minimally invasive, mesh-free system for pelvic organ prolapse repair. Uses the patented Finger Guide Delivery System to enable anchor placement through the vaginal wall and secure sutures to the sacrospinous ligament without deep dissection or mesh implants. Designed for same-day outpatient procedures for urogynecologists and pelvic floor reconstructive surgeons.
  • Elitone FDA-cleared external medical device for at-home treatment of stress urinary incontinence. Uses neuromuscular electrical stimulation through gel pads applied to the perineal area to tone pelvic floor muscles, worn 20 minutes daily for 6 weeks. Sold directly to consumers via femselect.com for $36/month subscription or $429 one-time purchase, with HSA/FSA eligibility and Original Medicare Part B coverage.
  • Elitone URGE FDA-cleared external medical device for at-home treatment of urge urinary incontinence and overactive bladder. Uses calming neuromuscular electrical stimulation to reduce sudden urges to urinate, applied 20 minutes daily for 6 weeks. FDA-cleared for over-the-counter use without prescription, sold direct-to-consumer at the same pricing as Elitone.
  • VNEW Precut decellularized dermal allograft for pelvic reconstruction procedures. Distributed by FEMSelect through the ARMS Medical partnership to complement the EnPlace surgical system.
  • DermaPure Dermal allograft product for pelvic reconstruction procedures. Distributed by FEMSelect through the ARMS Medical partnership to complement the EnPlace surgical system.

Quantifiable outcome

  • 6,000+ procedures performed globally
  • +6 more outcomes

Companies that use FEMSelect

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles2 records

FEMSelect technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

FEMSelect partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • medikanaminorChannel Partner/ Reseller/ Distributor · 1 January 2026Market research and distributor identification partner supporting FEMSelect's Latin America expansion. medikana helped identify exclusive distribution partners in key markets including Mexico, Chile, Costa Rica, and Panama.
  • ARMS MedicalcoreChannel Partner/ Reseller/ Distributor · 16 December 2025Strategic distribution agreement for biologic implant portfolio including VNEW precut decellularized dermal allografts and DermaPure products for pelvic reconstruction. ARMS Medical brings experience treating over 10,000 patients and engaging 200 surgeons nationwide. The partnership complements EnPlace and represents FEMSelect's capital-efficient strategy to build a diversified platform.
  • ElidahcoreChannel Partner/ Reseller/ Distributor · 22 September 2025Strategic partnership to distribute Elitone and Elitone URGE, FDA-cleared at-home devices for urinary incontinence treatment. This partnership expands FEMSelect's portfolio from EnPlace (surgical prolapse repair) into the incontinence market, addressing a condition affecting nearly one in three women. The agreement supports FEMSelect's growth strategy to build a comprehensive platform of women's health solutions.
  • Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 July 2025National group purchasing agreement providing FEMSelect access to Premier's network of healthcare providers. Premier serves approximately two-thirds of all healthcare providers in the United States, enabling broader adoption of EnPlace as a minimally invasive treatment option.

Scale indicators14 records

Recent moves8 records

Expansion highlights7 records

FEMSelect competitors and assessment

Company assessment

Direct peers

  • Axonics Modulation Technologies: Axonics acquired Bulkamid (hydrogel urethral bulking for SUI) from Contura in 2021 for $200M. Directly comparable: Bulkamid and EnPlace both target the same urogynecology/female pelvic medicine surgeon base for stress urinary incontinence and apical prolapse, with the same physician training and GPO distribution model. FEMSelect board member Rakesh Tailor led the Bulkamid-to-Axonics exit, making this the closest comparable.
  • Caldera Medical: Private women's health medtech company focused exclusively on pelvic floor disorders, offering Desara and Vertessa sling systems for stress urinary incontinence and Desara Pro for pelvic organ prolapse. Highly comparable as a similarly-sized specialty player competing in the same FPMRS surgeon channel with single-incision pelvic floor fixation devices.
  • InControl Medical: Maker of Apex and Attain at-home neuromuscular stimulation devices for stress and urge incontinence, FDA-cleared for OTC use. Directly competes with FEMSelect's distributed Elitone and Elitone URGE products in the same direct-to-consumer channel at comparable price points, addressing the same female urinary incontinence patient population.

Broad incumbents

  • Coloplast: Global medtech incumbent with a dedicated Pelvic Floor Health franchise offering Restorelle mesh, Altis single-incision sling, and surgical continence products. FEMSelect's CCO Joel Chechik previously led sales at Coloplast, and the companies target the same FPMRS surgeon base with overlapping pelvic floor fixation and incontinence offerings, though Coloplast operates at vastly greater scale across multiple product lines.
  • Boston Scientific: Major medtech incumbent with a Pelvic Health segment offering mid-urethral slings, mesh products, and the Xenform biologic matrix for pelvic reconstruction. Comparable because it competes with both EnPlace (surgical POP repair) and FEMSelect's ARMS Medical biologic implants (VNEW/DermaPure) for hospital budget and physician mindshare.
  • Ethicon (Johnson & Johnson MedTech): J&J's surgical device arm and the historical leader in women's pelvic floor surgery, with the Gynecare TVT sling and Prolift mesh product families. Renee Selman (FEMSelect's Executive Chairwoman) was former Worldwide President of Ethicon Women's Health and Urology. Comparable as the dominant incumbent that EnPlace is positioned to displace for mesh-averse surgeons.
  • CooperSurgical: Women's health-focused subsidiary of CooperCompanies providing a broad portfolio including the Frigg, Restora, and Sundance sling systems for pelvic floor disorders. Comparable as a diversified women's health platform serving the same urogynecology specialist base, though CooperSurgical spans fertility, obstetrics, and surgical solutions beyond pelvic floor.

Emerging players

  • Atlantic Therapeutics: Developer of the INNOVO non-invasive pelvic floor stimulation device for stress urinary incontinence, sold primarily via direct-to-consumer channels in Europe and the US. Comparable as a non-surgical, at-home electrical stimulation alternative competing with Elitone for the same conservative-treatment patient segment.
  • Renovia: Boston-based women's health startup developing the leva Pelvic Health System, an FDA-cleared digital pelvic floor training device for stress urinary incontinence. Comparable as a venture-backed, single-focus women's pelvic health company with both a connected device offering and physician-channel distribution competing for similar patient and provider mindshare.

Regional players

  • Neomedic International: Spain-based medical device company specializing in pelvic floor reconstruction products including the Contasure and Needleless single-incision sling systems. Comparable as a specialty competitor offering minimally invasive mesh and sling alternatives for POP and SUI, primarily serving European and Latin American markets where FEMSelect is now expanding via distribution partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

FEMSelect social profiles

Digital presence

FEMSelect compliance and trust

Trust signal

Compliance2 records

FEMSelect financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FEMSelect leadership team

Management profile

Number of profiles

Profiles14 records

FEMSelect funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FEMSelect M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FEMSelect

What does FEMSelect do?

FEMSelect develops, manufactures, and distributes medical devices for women's pelvic health. Its core product is the EnPlace system, an FDA-cleared, minimally invasive, mesh-free device for pelvic organ prolapse repair that uses a patented Finger Guide delivery system to anchor sutures to the sacrospinous ligament without deep dissection. The company also distributes Elitone and Elitone URGE, FDA-cleared at-home neuromuscular stimulation devices for stress and urge urinary incontinence, and biologic implants (VNEW, DermaPure) through a partnership with ARMS Medical.

Is FEMSelect a public or private company?

FEMSelect is a private company. It is classified as venture growth investor backed and is currently operating.

When was FEMSelect founded?

FEMSelect was founded in 2012. It employs 11 to 50 people.

Where is FEMSelect based?

FEMSelect is headquartered in New York, United States, in the North America region.

How does FEMSelect make money?

Three revenue lines are on record. EnPlace Medical Device Sales are the primary driver. The others are elitone Consumer Device Sales and biologic Implant Distribution.

Who are FEMSelect's main competitors?

Direct peers on record are Axonics Modulation Technologies, Caldera Medical and InControl Medical. Broad incumbents are Coloplast, Boston Scientific, Ethicon (Johnson & Johnson MedTech) and CooperSurgical. Emerging players are Atlantic Therapeutics and Renovia. Neomedic International is listed as a regional player.

Does FEMSelect have an API?

No public API is recorded for FEMSelect.

What industry is FEMSelect in?

FEMSelect's product category is Women's Pelvic Health Medical Devices. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS), with a secondary code of HLAKAJAE, Urogynecology & Pelvic Reconstructive Surgery (Female Pelvic Medicine). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFEMSelect Expands Pelvic Health Platform Through Strategic Distribution Agreement with ARMS MedicalFEMSelect, a women-led medical technology company focused on women's pelvic health, announced a strategic distribution agreement with ARMS Medical to distribute the latter's biologic implant portfolio for pelvic reconstruction, including VNEW\® precut decellularized dermal allografts and DermaPure\® products. The partnership complements FEMSelect's existing EnPlace\® system for pelvic organ prolapse repair and expands its commercial offerings to surgeons, with ARMS Medical bringing experience treating over 10,000 patients and engaging 200 surgeons nationwide. The agreement represents FEMSelect's continued capital-efficient strategy to build a diversified platform in women's health through portfolio expansion.PR NewswireFEMSelect Expands Women's Health Portfolio with Elidah Partnership to Distribute Elitone®FEMSelect announced a strategic partnership with Elidah to distribute the FDA-cleared Elitone® device for treating urinary incontinence, expanding its women's health portfolio beyond its flagship EnPlace® prolapse treatment. Elitone® uses electrical stimulation to treat stress and urge incontinence at home for 20 minutes daily over six weeks, addressing a condition affecting nearly one in three women. The partnership follows FEMSelect's oversubscribed Series B financing and supports its growth strategy including commercial team expansion and additional portfolio acquisitions.FemselectFEMSelect Expands Women’s Health Portfolio with Elidah Partnership to Distribute Elitone®FEMSelect, a privately held women-led company focused on pelvic health, announced a strategic partnership with Elidah to distribute Elitone®, FDA-cleared medical devices for at-home treatment of urinary incontinence. The agreement expands FEMSelect's portfolio beyond its flagship EnPlace® product for pelvic organ prolapse into the incontinence market, a condition affecting nearly one in three women. The partnership follows FEMSelect's oversubscribed Series B financing and supports its growth strategy to build a comprehensive platform of women's health solutions.PR NewswireFEMSelect Poised for Market Leadership with Strategic Advancements in Women's HealthFEMSelect announced an oversubscribed Series B equity financing to drive commercial growth and global expansion. The round was led by New Age Ventures and Triventures, with new investors including Nordwand Capital and Avea Ventures. The company will relocate its headquarters from Israel to the U.S. and appoint Sasha Schrode as CEO.Contemporary OB/GYNNovel devices for management of pelvic organ prolapseThis article reviews three novel medical devices for surgical treatment of pelvic organ prolapse (POP): the EnPlace system (FEMSelect), the Escala device (Escala Medical), and the StitchKit (Origami Surgical), all designed to reduce adverse events associated with traditional reconstructive pelvic surgery. These transvaginal percutaneous and robotic-assisted innovations offer alternatives to conventional hysterectomy and abdominal sacral colpopexy, with the potential to lower morbidity, decrease operative complications, and improve patient recovery times. While long-term durability studies remain pending, the article suggests these emerging technologies represent a shift toward safer, less invasive surgical approaches in pelvic floor reconstruction.GlobeNewswireLevLane Advertising Appointed Agency of Record by FEMSelect Ahead of Consumer Advocacy CampaignFEMSelect appointed LevLane Advertising as its agency of record to lead the U.S. consumer advocacy campaign for EnPlace, a minimally invasive pelvic floor ligament fixation system. The campaign will target women with pelvic organ prolapse, a condition affecting 30-50% of women in their lifetimes.FinSMEsFEMSelect Raises US$9M in Series B FinancingFEMSelect, a Tel Aviv-based pelvic floor ligament fixation developer, raised US$9M in Series B funding led by New Age Ventures and TriVentures. The company will use the funds to support growth and market penetration of its EnPlace® system in the US, which is FDA-cleared for uterine prolapse management.PR NewswireWomen's Health Leader FEMSelect Secures US$9M Series B FinancingFEMSelect completed a US$9M Series B funding round led by New Age Ventures, with TriVentures co-leading. The funds will expand commercialization of its EnPlace® minimally invasive prolapse repair system, which has a 92.3% apical repair success rate at four years. The company plans to focus on US market penetration.VatorNewsFEMSelect raises $9M to expand its pelvic floor fixation deviceFEMSelect secured a $9 million Series B funding round led by New Age Ventures to expand its EnPlace pelvic floor fixation device. The company plans to use the capital to deepen its presence in the US market and explore international expansion into Europe, Australia, and China. This funding brings FEMSelect's total raised to approximately $14 million as it aims to grow its women's health technology business.PR NewswireFour Year Study Shows Sustainable Long-Term Success for EnPlace® Minimally Invasive Meshless Approach to Pelvic Floor Ligament FixationFEMSelect reported positive results from a four-year prospective study of its EnPlace minimally invasive meshless pelvic floor ligament fixation system. The study of 13 women aged 48-82 with advanced pelvic organ prolapse found a 92.3% surgical success rate, with no interoperative complications or new bowel symptoms.